Fosamax Weakens Bones

Byron's Comments:

The mode of operation of Fosamax predicts that it will weaken bones with long-term use - and information from long-term users is now showing this to be the case.

Study Title:

Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.

Study Abstract:

We carried out a retrospective review over ten months of patients who had presented with a low-energy subtrochanteric fracture. We identified 13 women of whom nine were on long-term alendronate therapy and four were not. The patients treated with alendronate were younger, with a mean age of 66.9 years (55 to 82) vs 80.3 years (64 to 92) and were more socially active. The fractures sustained by the patients in the alendronate group were mainly at the femoral metaphyseal-diaphyseal junction and many had occurred after minimal trauma. Five of these patients had prodromal pain in the affected hip in the months preceding the fall, and three demonstrated a stress reaction in the cortex in the contralateral femur. Our study suggests that prolonged suppression of bone remodelling with alendronate may be associated with a new form of insufficiency fracture of the femur. We believe that this finding is important and indicates the need for caution in the long-term use of alendronate in the treatment of osteoporosis.

Study Information:

Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br.  2007 March  89(3):349-53.
Department of Orthopaedic Surgery, Singapore General Hospital, Outram Road, Singapore, Republic of Singapore.

My cart is empty.   View Cart |  Login

• How Protein Helps Weight Loss

• The Five Rules of The Leptin Diet

• The Facts on Magnesium Stearate

• What is Leptin?

• Taking Q10 for a Test Drive – Is Ubiquinol Better?